The cost-effectiveness of mild hypercapnia after out-of-hospital cardiac arrest: a health economic evaluation alongside the TAME study

YY Lee; G Eastwood; MJ Bailey; R Bellomo; AD Nichol; RL Parke; S McGuinness; S Bernard; YM Arabi; G Capellier; YW Chia; A Grejs; M Hænggi; D Kutsogiannis; G Landoni; A Markota; N Nielsen; T Olasveengen; MB Skrifvars; F Taccone; MP Wise; AM Higgins

Journal article

The cost-effectiveness of mild hypercapnia after out-of-hospital cardiac arrest: a health economic evaluation alongside the TAME study

YY Lee, G Eastwood, MJ Bailey, R Bellomo, AD Nichol, RL Parke, S McGuinness, S Bernard, YM Arabi, G Capellier, YW Chia, A Grejs, M Hænggi, D Kutsogiannis, G Landoni, A Markota, N Nielsen, T Olasveengen, MB Skrifvars, F Taccone Show all

Resuscitation | Published : 2025

DOI: 10.1016/j.resuscitation.2025.110878

Abstract

Background: Out of hospital cardiac arrest (OHCA) is a significant public health problem associated with high mortality and high healthcare costs. The Targeted Therapeutic Mild Hypercapnia after Resuscitated Cardiac Arrest (TAME) randomised clinical trial showed that targeted mild hypercapnia did not lead to better neurologic outcomes at 6 months compared to normocapnia after OHCA. We aimed to estimate the cost-effectiveness of mild hypercapnia compared to targeted normocapnia using data from the TAME trial. Methods: Pre-specified, prospective cost-effectiveness analysis alongside the TAME RCT from a healthcare perspective using a 6-month time horizon. The analysis included 1586 patients acr..

View full abstract